NPAA Takes Action Against 93 Drug Brands (India)
This article was originally published in PharmAsia News
India's National Pharmaceutical Pricing Authority (NPAA) has instituted a serious crackdown on drug companies who promised to cut prices but have not done so. Previously, the pharmaceutical manufacturers made an agreement with the agency to reduce the price of 886 brands. Now, the NPAA has instituted fixed pricing for 37 brands. It is now also obligated the producers of 56 other brands to reimburse the government for the amount they overcharged. According to NPAA representatives, this is only the beginning. A survey of 12 of the countries largest cities found approximately half of the 574 samples were also guilty of overcharging. (Click here for more
You may also be interested in...
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.